官网网址:www.chemegen.com ACT-389949 is a first-in-class, potent and selective and agonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2/ALX internalization into monocytes. ACT-389949 has potential for the treatment of inflammatory disorders. ChemeGen 作为优秀的抑制剂、激动剂及新型生命科学试剂的供应商,致力于为广大科研、商业实验室的科学研究者提供高品质的产品与技术服务,不断促进生命科学领域的新技术发展。